Advances in the knowledge and clinical applications of lactic acid bacteria as probiotics in the urogenital tract

Current Women's Health Reviews

Volumn 4, Issue 4, 2008, Pages 240-257

  Nader Macías, María Elena Fátima ^a   de Ruiz, Clara Silva ^c   Ocaña, Virginia S ^b   Tomás, María Silvina Juárez ^a  

^a CENTRO DE REFERENCIA PARA LACTOBACILOS CERELA CONICET   (Argentina)

^b Hospital del Milagro   (Argentina)

^c UNIVERSIDAD NACIONAL DE TUCUMÁN   (Argentina)

Author keywords

Clinical trials; In vivo assays; Lactic acid bacteria; Probiotics; Urogenital tract

Indexed keywords

ACYLGLYCEROL; ALLICIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIPARASITIC AGENT; ANTIVIRUS AGENT; ASCORBIC ACID; BORIC ACID; CALAGIN; CASEIN; CELLULOSE; CLINDAMYCIN; COTRIMOXAZOLE; ECOVAGFLORA; ESTRIOL; FEM DOPHILUS; FEMALAC; FEMILAC; GELATIN; GENE FILUS F19; GINLAC V; GLUCOSE; GY NA TREN; GYNOFLOR; HLC CANDACLEAR; HYDROXYPROPYLMETHYLCELLULOSE; INTRAFRESH; LACTINEX; LACTITOL; LACTOBAC; LACTOFEM; LACTONORM; LACTOSE; MACROGOL; MAGNESIUM STEARATE; METRONIDAZOLE; MICROCRYSTALLINE CELLULOSE; NORFLOXACIN; POTATO STARCH; PROBIOTIC AGENT; PROGESTERONE; SILICON DIOXIDE; TITANIUM DIOXIDE; TRICHOMONIASIS VACCINE; TROPIVAG; TROPIVAG PLUS; ULTIMATE FLORA VAGINAL SUPPORT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAGIFLOR; XANTHAN; ZHLEMIK;

BACTEROIDES; CANDIDA ALBICANS; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONDYLOMA ACUMINATUM; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; EXPERIMENTAL MODEL; FEMALE GENITAL SYSTEM; GARDNERELLA VAGINALIS; GENITAL HERPES; GONORRHEA; HAEMOPHILUS DUCREYI; HEPATITIS B; HEPATITIS B VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KLEBSIELLA PNEUMONIAE; LACTIC ACID BACTERIUM; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS FERMENTUM; LACTOBACILLUS GASSERI; LEPTOTRICHIA; LISTERIA MONOCYTOGENES; LISTERIOSIS; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; MYCOPLASMA HOMINIS; NEISSERIA GONORRHOEAE; PEPTOSTREPTOCOCCUS; PREMATURE LABOR; PRIORITY JOURNAL; PROTEUS MIRABILIS; RECOMMENDED DRUG DOSE; REVIEW; SEXUALLY TRANSMITTED DISEASE; STAPHYLOCOCCUS SAPROPHYTICUS; STREPTOCOCCUS AGALACTIAE; SYPHILIS; TREPONEMA PALLIDUM; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; ULCUS MOLLE; URINARY TRACT INFECTION; UROGENITAL TRACT INFECTION; VAGINA CANDIDIASIS; VAGINA FLORA; VAGINITIS; WART VIRUS;

EID: 60649083400     PISSN: 15734048     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340408786848214     Document Type: Review

References (110)

1. Witkin SS, Linhares IM, Giraldo P. Bacterial flora of the female genital tract: function and immune regulation. Best Pract Res Clin Obstet Gynaecol 2007; 21: 347-54.
2. Forsum U, Hallén A, Larsson PG. Bacterial vaginosis-a laboratory and clinical diagnostics enigma. APMIS 2005; 113: 153-61.
3. Larsson P, Stray-Pedersen B, Ryttig K, Larsen S. Human lactobacilli as supplementation of clindamicyn to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind randomized, placebo-controlled study. BMC Women's Health 2008; 8: 3.
4. Odds FC. Candidiasis of the genitalia. In: Odds FC Ed, Candida and candidiasis: A review and bibliography, 2nd ed. London, Bailliére Tindall 1988; 124.
5. Falagas ME, Betsi GI, Tokas T, Athanasiou S. Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies. Drugs 2006; 66: 1253-61.
6. OMS. Organizacion Mundial de la Salud. Guías para el tratamiento de las infecciones de transmision sexual. Suiza, 2005.
7. Weir E. Upsurge of genital Chlamydia trachomatis infection. Can Med Assoc J 2004; 17: 855.
8. Adler M, Cowan F, French P, Mitchel H, Richens J. In: Adler M, Cowan F, French P, Mitchel H, Richens J. Ed, ABC of Sexually Transmitted Infection. 5th ed, London, BMJ Books, 2005.
9. Puopolo K, Madoff L, Baker C. Group B streptococcal infection in pregnant women. In: Rose BD Ed, UpToDate Waltham, MA; 2006.
10. Weinstein K, Ortiz J. Listeria monocytogenes. E Medicine 2006.
11. Keck JW. Ulcerative Lesions. Clin Fam Pract 2005; 7: 13-30
12. Castle PE, Giuliano AR. Genital tract infections, cervical inflammation and antioxidant nutrients-assessing their roles as human papillomavirus cofactors. J Natl Cancer Inst Monogr 2003; 31: 29-34.
13. Karlsson R, Jonsson M, Edlund K, et al. Lifetime number of partners as the only independent risk factor for human Papilloma Virus Infection: a population-based study. Sex Trans Dis 1995; 22: 120-7.
14. Buccolo L. Viral Hepatitis. Clin Fam Pract 2005; 7: 105-25.
15. Fihn SD. Clinical practice. Acute uncomplicated urinary tract infection in women. N Engl J Med 2003; 349: 259-66.
16. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002; 113: 5S-13S.
17. Cram LF, Zapata MI, Toy EC, Baker B. Genitourinary infections and their association with preterm labour. Am Fam Physician 2002; 65: 241-8.
18. Chaim W, Mazor M, Leiberman JR. The relationship between bacterial vaginosis and preterm birth. A review. Arch Gynecol Obstet 1997; 259: 51-8.
19. Crowther CA, Thomas N, Middleton P, Chua M, Esposito M. Treating periodontal disease for preventing preterm birth in pregnant women. (Protocol). Cochrane Database Syst Rev 2005.
20. Kiss H, Petricevic L, Husslein P. Prospective randomised controlled trial of an infection screening programmed to reduce the rate of preterm delivery. BMJ 2004; 329: 371.
21. Klein LL, Gibbs RS. Use of microbial cultures and antibiotics in the prevention of infection-associated preterm birth. Am J Obstet Gynecol 2004; 190: 1493-502.
22. Reid G, Bruce AW. Urogenital infections in women; can probiotics help? Postgrad Med J 2003; 79: 428-34.
23. Romero R, Espinoza J, Chaiworapongsa T, Kalache K. Infection and prematurity and the role of preventive strategies. Semin Neonatol 2002; 7: 259-74.
24. Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The vaginal infections and prematurity study group. N Engl J Med 1995; 333: 1737-42.
25. Reid G. Probiotic agents to protect the urogenital tract against infection. Am J Clin Nutr 2001; 73: 437-43.
26. Leitich H, Bodner-Adler B, Brunbauer M, Kaider A, Egarter C, Husslein P. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol 2003; 189: 139-47.
27. Reid G, Bocking A. The potential for probiotics to prevent bacterial vaginosis and preterm labor. Am J Obstet Gynecol 2003; 189: 1202-8.
28. Sewankambo N, Gray RH, Wawer MJ, et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 1997; 350: 546-50.
29. Hillier, SL. The vaginal microbial ecosystem and resistance to HIV. AIDS Res Hum Retroviruses 1998; 14: S17-21.
30. Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 1999; 180: 1863-8.
31. Schmid G, Morcowitz L, Joesoef R, Koumans E. Bacterial vaginosis and HIV infection. Sex Transm Infect 2000; 76: 3-4.
32. Van De Wijgert JH, Mason PR, Gwansura L, et al. Intravaginal practices, vaginal flora disturbances, and adquisition of sexually transmitted diseases in Zimbabwean women. J Infect Dis 2000; 181: 587-94.
33. Reid G, Sanders ME, Gaskins R et al. New Scientific paradigms for probiotics and prebiotics. J Clin Gastroenterol 2003; 37: 108-18.
34. Savage DC, Kotarski SF. Models for study the specificity by which lactobacilli adhere to murine gastric epithelium. Infect Immun 1979; 26: 966-73.
35. Morelli L. In vitro selection of probiotic lactobacilli: a critical appraisal. Curr Issues Intest Microbiol 2000; 1: 59-67.
36. Vaughan EE, Heilig HG, Ben-Amor K, De Vos WM. Diversity, vitality and activities of intestinal lactic acid bacteria and bifidobacteria assessed by molecular approaches. FEMS Microbiol Rev 2005; 29: 477-90.
37. Reid G, Jass J, Sebulsky TM, Mc Cormick JK. Potential uses of probiotics in clinical practice. Clin Microb Rev 2003; 16: 658-72.
38. Sanders ME, Guarner F, Mills D, et al. Selected topics in probiotics and prebiotics: meeting report for the 2004 international scientific association for probiotics and prebiotics. Curr Issues Intest Microbiol 2005; 6: 55-68.
39. Ocaña VS, Bru E, Ruiz Holgado A, Nader-Macías ME. Surface characteristics of lactobacilli isolated from human vagina. J Gen Appl Microbiol 1999; 45: 203-12.
40. Pavlova S, Kilic A, Kilic S, et al. Genetic diversity of vaginal lactobacilli from women in different countries based on 16S rRNA gene sequences. J Appl Microbiol 2002; 92: 451-9.
41. Antonio MAD, Hillier SF. DNA Fingerprinting of Lactobacillus crispatus strain CTV-05 by Repetitive Elements Sequence-Based PCR Analysis in a Pilot Study of Vaginal Colonization. J Clin Microbiol 2003; 41: 1881-7.
42. Devillard E, Burton JP, Hammond JA, Lam D, Reid G. Novel insight into the vaginal microflora in postmenopausal women under hormone replacement therapy as analyzed by PCR-denaturing gradient gel electrophoresis. Eur J Obstet Gynecol Reprod Biol 2004; 117: 76-81.
43. Stoyancheva GD, Danova ST, Boudakov IY. Molecular identification of vaginal lactobacilli isolated from Bulgarian women. Antonie Van Leeuwenhoek 2006; 90: 201-10.
44. Nagy E, Froman G, Mardh P. Fibronectin binding of lactobacillus species isolated from women with or without bacterial vaginosis. J Med Microbiol 1992; 37: 38-42.
45. Ocaña V, Nader-Macías ME. Adhesion of Lactobacillus vaginal strains with probiotic properties to vaginal epithelial cells. Biocell 2001; 25: 265-73.
46. Ocaña VS, Nader-Macías ME. Vaginal Lactobacilli: self and coaggregating ability. Br J Biomed Sci 2002; 59: 183-90.
47. Juárez Tomás MS, Wiese B, Nader-Macias ME. Effects of culture conditions on the growth and autoaggregation ability of vaginal Lactobacillus jonhsonii CRL 1294. J Appl Microbiol 2005; 99: 1383-91.
48. Castagliulo I, Galeazzi F, Ferrari S, et al. Beneficial effect of auto-aggregating Lactobacillus crispatus on experimentally induced colitis in mice. FEMS Immun Med Microbiol 2005; 43: 197-204.
49. 2 generating Lactobacillus species for probiotic use. Curr Microbiol 1999; 38: 279-84.
50. 2-producing Lactobacillus paracasei subsp. paracasei isolated from the human vagina. FEMS Immunol Med Microbiol 1999; 23: 87-92.
51. Ocaña V, Ruiz Holgado A, Nader-Macías ME. Characterization of a bacteriocin-like substance produced by a vaginal Lactobacillus salivarius strain. Appl Environ Microbiol 1999; 65: 5631-5.
52. Vera Pingitore E, Salvucci E, Sesma F, Nader-Macías ME. Different strategies for purification of antimicrobial peptides from Lactic Acid Bacteria (LAB). In: Méndez-Vilas A Ed, Communicating Current Research and Educational Topics and Trends in Applied Microbiology 2007; 1: 557-68.
53. Dover SE, Aroutcheva AA, Faro S, Chikindas ML. Safety study of an antimicrobial peptide lactocin 160, produced by the vaginal Lactobacillus rhamnosus. Infect Dis Obstet Gynecol 2007; 2007: 78248.
54. Juárez Tomás MS, Bru E, Wiese B, de Ruiz Holgado AAP, Nader-Macías ME. Influence of pH, temperature and culture media on the growth and bacteriocin production of vaginal Lactobacillus salivarius CRL 1328. J Appl Microbiol 2002; 93: 714-24.
55. Juárez Tomás MS, Bru E, Nader-Macías ME. Comparison of the growth and hydrogen peroxide production by vaginal probiotic lactobacilli under different culture conditions. Am J Obstet Gynecol 2003; 188: 35-44.
56. Juárez Tomás MS, Ocaña V, Wiese B, Nader-Macías ME. Growth and lactic acid production by vaginal Lactobacillus acidophilus CRL 1259. Inhibition of uropathogenic Escherichia coli. J Med Microbiol 2003; 52: 1117-24.
57. Famularo G, Pieluigi M, Coccia R, Mastroiacovo P, DeSimone C. Microecology, bacterial vaginosis and probiotics: perspectives for bacteriotherapy. Med Hypotheses 2001; 56: 421-30.
58. Cauci S, Guaschino S, Driussi S, De Santo D, Lanzafame P, Quadrifoglio F. Correlation of local interleukin-8 with immunoglobulin A against Gardnerella vaginalis hemolysin and with prolidase and sialidase levels in women with bacterial vaginosis. J Infect Dis 2002; 185: 1614-20.
59. Velraeds M, Van De Belt-Gritter B, Van Der Mei H, Reid G, Busscher H. Interference in initial adhesion of uropathogenic bacteria and yeasts to silicone rubber by a Lactobacillus acidophilus biosurfactant. J Med Microbiol 1998; 47: 1081-5.
60. Velraeds M, Van Der Mei H, Reid G, Busscher H. Inhibition of initial adhesion of uropathogenic Enterococcus faecalis by biosurfactants from Lactobacillus isolates. Appl Environm Microbiol 1996; 62: 1958-63.
61. Velraeds M, Van Der Mei H, Reid G, Busscher H. Inhibition of initial adhesion of uropathogenic Enterococcus faecalis to solid substrata by an adsorbed biosurfactant layer from Lactobacillus acidophilus. Urology 1997; 49: 790-4.
62. Reid G, Chan RCY, Bruce AW, Costerton JW. Prevention of urinary tract infection in rats with an indigenous Lactobacillus casei strain. Infect Immun 1985; 49: 320-24.
63. Nader-Macías ME, Lopez-Bocanera ME, Silva-Ruiz C, Pesce-Ruiz Holgado A. Isolation of lactobacilli from the urogenital tract of mice. Elaboration of beads for their inoculation. Microbiol-Aliments Nutr 1992; 10: 43-7.
64. Silva-Ruiz C, Nader-Macías ME, Lopez-Bocanera ME, Pesce-Ruiz Holgado A. Lactobacillus fermentum administered in suspensions and in agarose beads to mice: a comparative study. Microbiol-Aliments Nutr 1993; 11: 391-7.
65. Nader-Macías ME, Silva-Ruiz C, Lopez-Bocanera ME, Pesce-Ruiz Holgado A. Behaviour of lactobacilli on prevention and therapeutic effects on urinary tract infections (UTI) in mice. Anaerobe 1996; 2: 85-93.
66. Silva-Ruiz C, Lopez-Bocanera ME, Nader-Macías ME, Pesce-Ruiz Holgado A. Effect of lactobacilli and antibiotics on E. coli urinary infections in mice. Biol Pharm Bull 1996; 19: 88-93.
67. Silva de Ruiz C, Rey R, Nader-Macías ME. Experimental administration of estradiol on the colonization of Lactobacillus fermentum and Escherichia coli in the urogenital tract of mice. Biol Pharm Bull 2001; 24: 127-34.
68. Asahara T, Nomoto K, Watanuki M, Yokokura T. Antimicrobial activity of intraurethrally administered probiotic Lactobacillus casei in a murine model of Escherichia coli urinary tract infection. Antimicrob Agents Chemother 2001; 45: 1751-60.
69. Fraga M, Scavone P, Zunino P. Preventive and therapeutic administration of an indigenous Lactobacillus sp. strain against Proteus mirabilis ascending urinary tract infection in a mouse model. Antonie van Leeuwenhook 2005; 88: 24-34.
70. Vintiñi E, Ocaña V, Nader-Macías ME. Effect of lactobacilli administration in the vaginal tract of mice: evaluation of side effects and local immune response by local administration of selected strains. In: Spencer JFT, Ragout de Spencer AL Ed, Methods in Molecular Biology, Public Health Microbiology: Methods and Protocols. Totowa, NJ, Humana Press Inc, 2004; 268: 401-10.
71. Zárate G, Santos V, Nader-Macías ME. Protective effect of vaginal Lactobacillus paracasei CRL 1289 against urogenital infection produced by Staphylococcus aureus in a mouse animal model. Infect Dis Obstet Gynecol 2007; 2007: 48358.
72. Morelli L, Zonenschain D, Del Piano M, Cognein P. Utilization of the intestinal tract as delivery system for urogenital probiotics. J. Clin Gastroenterol 2004; 38: S107-10.
73. Reid G, Anukam K, James VI, et al. Oral Probiotic for maternal and newborn health. J Clin Gastroenterol 2005; 39: 353-4.
74. Colodner R, Edelstein H, Chazan B, Raz R. Vaginal colonization by orally administered Lactobacillus rhamnosus GG. Isr Med Assoc 2003; 5: 767-9.
75. Kanne B, Jenny J. Local administration of low-dose estriol and vital Lactobacillus acidophilus in postmenopause. Gynakol Rundsch1991; 31: 7-13.
76. Reid G, Beuerman D, Heinemann C, Bruce AW. Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora. FEMS Immunol Med Microbiol 2001; 32: 37-41.
77. Reid G, Bruce A, Fraser N, Heinemann C, Owen J, Henning B. Oral probiotics can resolve urogenital infections. FEMS Immunol Med Microbiol 2001; 30: 49-52.
78. Reid G, Charbonneau D, Erb J, et al. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol Med Microbiol 2003; 35: 131-4.
79. Ozkinay E, Terek MC, Yayci M, Kaiser R, Grob P. Tuncay G. The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections. BJOG 2005; 112: 234-40.
80. Czaja CA, Stapleton AE, Yarova-Yarovaya Y, Stamm WE. Phase I trial of a Lactobacillus crispatus vaginal suppository for prevention of recurrent urinary tract infection in women. Infect Dis Obstet Gynecol 2007; 2007: 35387.
81. Parent J, Bossens M, Bayot D, et al. Therapy of bacterial vaginosis using exogenously applied Lactobacillus acidophilus and a low dose of estriol. Drug Res 1996; 46: 68-73.
82. Anukam K, Osakuwa E, Ahonkhai I, et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double blind, placebo controlled trial. Microbes Infect 2006; 8: 1450-4.
83. Ozmen S, Turhan NO, Seckin NC. Gardnerella-associated vaginitis: Comparison of three treatment modalities. Turkish J Med Sci 1998; 28: 171-3.
84. Tsvetkov K, Vasileva P, Petkova U. Probiotics in the treatment and prevention of bacterial vaginosis relapses. Akush Ginekol 2007; 46: 41-4.
85. Dimitrova A, Shapova E, Timeba T. Gynalgin-one more opportunity in the treatment of Bacterial vaginosis. Akush Gynecol 2007; 46: 46-7.
86. Delia A, Morgate G, Rago, Musacchio MC, Petraglia F, De Leo V. Effectiveness of oral administration of Lactobacillus paracasei subsp. paracasei F19 in association with vaginal suppositories of Lactobacillis acidophilus in the treatment on vaginosis and in the prevention of recurrent vaginitis. Minerva Ginecol 2006; 58: 227-31.
87. Drago L, De Vecchi E, Nicola L, Zucchetti E, Gismondo MR, Vicariotto, F. Activity of a Lactobacillus acidophilus-based douche for the treatment of bacterial vaginosis. J Altern Complement Med 2007; 13: 435-8.
88. Eriksson K, Carlsson B, Forsum U, Larsson PG. A double-blind treatment stydy of bacterial vaginosis with normal vaginal lactobacilli after an open treatment with vaginal clindamycin ovules. Acta Derm Venereol 2005; 85: 42-6.
89. Chang TL, Chang CH, Simpson DA, et al. Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci USA 2003; 100: 11672-7.
90. Bolton M, van der Straten A, Cohen CR. Probiotics: potential to prevent HIV and sexually transmitted infections in women. Sex Transm Dis 2008; 35: 214-25.
91. Liu JJ, Reid G, Jiang Y, Turner MS, Tsai CC. Activity of HIV entry and fusion inhibitors expressed by the human vaginal colonizing probiotic Lactobacillus reuteri RC-14. Cell Microbiol 2007; 9: 120-30.
92. Pirotta M, Gunn J, Chondros P, Grover S, Hurley S, Garland S. The PAV trial: does lactobacilli prevent post-antibiotic vulvovaginal candidiasis? Protocol of a randomized controlled trial. BMC Fam Pract 2004; 5: 5.
93. Pirotta M, Gunn J, Chondros P. Lactobacilli does not prenvent post-antibiotic vaginitis. J Fam Pract 2004; 53: 952.
94. Pirotta M, Gunn J, Chondros P, Grover S, O'Malley P, Hurley S, Garland S. Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomized controlled trial. BMJ 2004; 329: 548.
95. Reid G, Bruce A, Taylor M. Influence of three days antimicrobial therapy and Lactobacilli vaginal suppositories on recurrence of Urinary Tract Infections. Clin Ther 1992; 14: 11-6.
96. Uehara S, Monden K, Nomoto K, Seno Y, Kariyama R, Kumon H. A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. Int J Antimicrob Agents 2006; 28: S30-4.
97. Baerheim S, Larsen E, Di Granes A. Vaginal application of lactobacilli in the prophylaxis of recurrent lower urinary tract infections in women. Scand J Prim Health Care 1994; 12: 239-42.
98. Reid G, Bruce AW. Probiotics to prevent urinary tract infections: the rationale and the evidence. World J Urol 2006; 24: 28-32.
99. Othman M, Neilson JP, Alfirevic Z. Probiotics for preventing preterm labour (Cochrane Review). In: The Cochrane Library, Issue 4, 2007.
100. Korshunov VM, Kafarskaia LI, Bagirova MSh, Minkina GN, Monukhin IB, Bossart W. The effect of Solco Trichovac on the vaginal microflora of patients with papillomavirus infection associated with a cervical intraepithelial neoplasm. Zh Mikrobiol Epidemiol Immunobiol 1994; 5:13-17.
101. Korshunov VM, Kafarskaia LI, Bagirova MSh, Minkina GN, Korshunova OV, Monukhin IB. The correlation of the vaginal microflora patients with papilloma virus infection associated with cervical intraepithelial neoplasia by using the new bacterial preparation Zhlemik. Zh Mikrobiol Epidemiol Immunobiol 1995; 4. 91-94.
102. Ronnqvist PD, Forsgren-Brusk UB, Grahn-Hakansson EE. Lactobacilli in the female genital tract in relation to other genital microbes and vaginal pH. Acta Obstet Gynecol Scand 2006; 5:726-35.
103. Patel Y, Gopalan S, Bagga R, Sharma M, Chopra S, Sethi S. A randomized trial comparing a polyherbal pessary (a complementary and alternative medicine) with Ginlac-V pessary (containing clotrimazole, tinidazole and lactobacilli) for treatment of women with symptomatic vaginal discharge. Arch Gynecol Obstet 2008; 278(4): 341-7.
104. Juárez Tomás MS, Bru de Labanda E, de Ruiz Holgado AP, Nader-Macías ME. Estimation of vaginal probiotic lactobacilli growth parameters with the application of the Gompertz model. Can J Microbiol 2002; 48: 82-92.
105. Maggi L, Mastromarino P, Macchia S, et al. Technological and biological evaluation of tablets containing different strains of lactobacilli for vaginal administration. Eur J Pharm Biopharm 2000; 50: 389-95.
106. Mastromarino P, Brigidi P, Macchia S, et al. Characterization and selection of vaginal Lactobacillus strains for the preparation of vaginal tablets. J Appl Microbiol 2002; 93: 884-93.
107. Zárate G, Juárez Tomás MS, Nader-Macías ME. Effect of some pharmaceutical excipients on the survival of probiotic vaginal lactobacilli. Can J Microbiol 2005; 51: 483-9.
108. Zárate G, Nader-Macías ME. Viability and biological properties of probiotic vaginal lactobacilli after lyophilization and refrigerated storage into gelatin capsules. Process Biochem 2006; 41: 1779-85.
109. Alam MA, Ahmad FJ, Khan ZI, Khar RK, Ali M. Development and evaluation of acid-buffering bioadhesive vaginal tablet for mixed vaginal infections. AAPS Pharm Sci Tech 2007; 8: 109.
110. Hughes VL, Hillier SL. Microbiological characteristics of Lactobacillus products used for colonization of the vagina. Obstet Gynecol 1990; 75: 244-8.